Why would GlaxoSmithKline (LSE: GSK) (NYSE: GSK.US), one of the world’s largest pharmaceutical companies, want to get out of the business of treating cancer? Following its deal with Novartis, that’s exactly what it has done… in this video, Owain Bennallack explains why he thinks it is a strong move.
https://youtu.be/yc35AtePuOI